Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2014 1
2019 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.
Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F. Phyo AP, et al. Clin Infect Dis. 2011 Nov;53(10):977-84. doi: 10.1093/cid/cir631. Clin Infect Dis. 2011. PMID: 22002979 Free PMC article. Clinical Trial.
BACKGROUND: Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative treatments are requi …
BACKGROUND: Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially conf …
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
Awab GR, Pukrittayakamee S, Imwong M, Dondorp AM, Woodrow CJ, Lee SJ, Day NP, Singhasivanon P, White NJ, Kaker F. Awab GR, et al. Malar J. 2010 Apr 21;9:105. doi: 10.1186/1475-2875-9-105. Malar J. 2010. PMID: 20409302 Free PMC article. Clinical Trial.
METHODS: Between July 2007 and February 2009, an open-label, randomized controlled trial of chloroquine and dihydroartemisinin-piperaquine in patients aged three months and over with slide-confirmed P. vivax mono-infections was con …
METHODS: Between July 2007 and February 2009, an open-label, randomized controlled trial of chloroquine and d …
Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial.
Degaga TS, Pasaribu AP, Tripura R, Ghanchi N, Rajasekhar M, Adhikari B, Ley B, Bamboro SA, Jabbar FA, Hasibuan N, Tego TT, Zehra S, Qurashi B, Mnjala H, Lee G, Li P, Kazi AM, Safitri W, Yulita Y, Siagian DSP, Syahputra D, Hadi H, Muhammad T, Ibrahim A, Syed N, Dost K, Puspitrasari AM, Kariodimedjo PP, Rai A, Rumaseb A, Sutanto E, Ean M, Khan A, Sokha M, Commons RJ, Weston S, Noviyanti R, Peto T, Callery JJ, Ali U, Mehmood T, Dondorp A, Devine A, Setiawan E, Mwaura M, Cassidy-Seyoum S, Temesgen R, Abate DT, Erjabo EB, Gessa GG, Kiros FG, Usmani MI, Raza A, Woyessa A, Hailu A, Simpson JA, Karahalios A, Beg MA, von Seidlein L, Dysoley L, Auburn S, Price RN, Thriemer K. Degaga TS, et al. Lancet Infect Dis. 2026 Jun;26(6):614-626. doi: 10.1016/S1473-3099(25)00729-7. Epub 2026 Feb 11. Lancet Infect Dis. 2026. PMID: 41690325 Free PMC article. Clinical Trial.
BACKGROUND: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmodium vivax infections, but there are few data on their comparative effectiveness when provided unsupervised. ...Patients were treated wi …
BACKGROUND: Shorter courses of primaquine and single-dose tafenoquine have potential to improve the prevention of recurrent Plasmodium …
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Gogtay N, et al. Cochrane Database Syst Rev. 2013 Oct 25;2013(10):CD008492. doi: 10.1002/14651858.CD008492.pub3. Cochrane Database Syst Rev. 2013. PMID: 24163021 Free PMC article.
BACKGROUND: Plasmodium vivax is an important cause of malaria in many parts of Asia and South America, and parasite resistance to the standard treatment (chloroquine) is now high in some parts of Oceania. This review aims to assess the current …
BACKGROUND: Plasmodium vivax is an important cause of malaria in many parts of Asia and South America, and parasite res …
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, Thinraow S, Wilairisak P, Raksapraidee R, Carrara VI, Paw MK, Wiladphaingern J, Proux S, Bancone G, Sriprawat K, Lee SJ, Jeeyapant A, Watson J, Tarning J, Imwong M, Nosten F, White NJ. Chu CS, et al. Clin Infect Dis. 2019 Apr 8;68(8):1311-1319. doi: 10.1093/cid/ciy735. Clin Infect Dis. 2019. PMID: 30952158 Free PMC article. Clinical Trial.
BACKGROUND: Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. ...METHODS: Patients with uncomplicated P. vivax malaria on the Thailand …
BACKGROUND: Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of tr …
Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.
Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, Chotsiri P, Wattanakul T, Panapipat S, Lee SJ, Day NP, White NJ. Hanboonkunupakarn B, et al. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6. doi: 10.1128/AAC.03704-14. Epub 2014 Sep 29. Antimicrob Agents Chemother. 2014. PMID: 25267661 Free PMC article. Clinical Trial.
Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combinat …
Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplic …